Renovorx, Inc.

RNXT · Nasdaq · ·

Vergelijken

US$ 1,05-9,9%slot 13 nov

Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 5 november 2026

1W: -7,5%
1M: -6,7%

Just reported

Q3 2026 results

From Renovorx's results release of 5 november 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 1,1M
+301% y/y
+17% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$ -0,08
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -3,2M
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$ 3,75M – US$ 4,25M+256% y/y Raised +14%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Renovorx is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Volledige jaarrekening →

Gebouwd uit de eigen deponeringen van Renovorx, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.

Renovorx, Inc.

Renovorx, Inc.

Q3 2026 results

Revenue

EPS, GAAP